IMIO, a startup developing biologicals that break down crop residues to release nutrients that can boost crop yields and…

Evaxion reports sustained cancer vaccine responses at three years: Denmark’s Evaxion said all six patients in a Phase 2 extension maintained their responses without tumor progression after three years. The advanced melanoma patients received personalized peptide vaccine EVX-01 alone during the third year, following two years alongside Keytruda. The original 16-patient trial reported a 75% response rate with 25% of patients obtaining a complete response. The durability signal is encouraging, but the extension included only six of the 12 responders. Further findings will be presented at ESMO on October 24. Evaxion’s shares jumped 21.6% on Monday following the company’s announcement.

Kodama—a California-based startup building physical AI for forestry—has raised a $7 million seed round to accelerate its…

Cosmax is using its microbiome research to enter the wellness and pharmaceutical markets through a partnership with Harvard Medical School researchers. The Korean beauty manufacturer’s push beyond cosmetics into biotech and medicine comes as demand for weight-loss drugs and clinical anti-aging rises. 

The acquisition gives AM-Pharma’s ilofotase alfa another chance after setbacks in kidney disease. It also illustrates Ambrose’s strategy: acquire stalled compounds with existing human data and develop them for rare diseases, aiming to reduce the time and cost of bringing treatments to market.

40 FAO will host the Africa Science and Innovation Forum from 27–29 October 2026 in Addis Ababa, Ethiopia, bringing toge…

Why it matters: Roche is expanding its collaboration with Chinese pharmaceutical company Hansoh. A year after their first agreement covering an antibody-drug conjugate (ADC) candidate, the two companies have now agreed to another, substantially broader development and licensing partnership. It covers a wide portfolio of ADC programs targeting various cancers. Hansoh could receive more than $15 billion in total development, regulatory and commercialization milestone payments, as well as sales-based royalties. In addition, it will receive a $400 million upfront payment and a further $110 million on the agreement’s first anniversary.

The deal: The purchase price is $20 per American Depositary Share (ADS) in cash. This corresponds to an equity value of approximately $1.3 billion and an enterprise value of about $1.1 billion. The transaction is expected to close in the first quarter of 2027, subject to customary conditions, including approval by Silence shareholders and regulatory clearances. It is to be financed through new debt.

The UK government this week announced a new set of proposed regulations hiking guardrails against unqualified personnel from carrying out cosmetic procedures in England.